SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1(b), (c) AND (d)
AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. __) *
Acadia Pharmaceuticals Inc.
----------------------------------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
004225108
---------
(CUSIP Number)
August 20, 2004
---------------
Date of Event which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 2 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
Biotechnology Value Fund, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY -----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 265,500 shares
WITH
----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
265,500 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
265,500 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.57%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
PN
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 3 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
Biotechnology Value Fund II, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY ----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 168,500 shares
WITH ----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
168,500 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
168,500 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.00%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
PN
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 4 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
BVF Investments, L.L.C.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY -----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 407,000 shares
WITH -----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
-----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
407,000 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
407,000 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.41%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
OO
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 5 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
Investment 10, LLC
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY ----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 44,000 shares
WITH
----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
44,000 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
44,000 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.26%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
OO
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 6 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
BVF Partners L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY ----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 885,000 shares
WITH
----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
885,000 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
885,000 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.24%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
PN
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 7 of 11 Pages
- -------------------------------- --------------------------
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
BVF Inc.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (entities only)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) [X]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF
SHARES 0
BENEFICIALLY ----------------------------------------------------------------
OWNED BY
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 885,000 shares
WITH ----------------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
----------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
885,000 shares
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
885,000 shares
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
[ ]
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.24%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
CO
- --------------------------------------------------------------------------------
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 8 of 11 Pages
- -------------------------------- --------------------------
Item 1(a). Name of Issuer:
Acadia Pharmaceuticals Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
3911 Sorrento Valley Blvd.
San Diego, CA 92121
Item 2(a). Names of Person Filing
This Schedule 13G is being filed on behalf of the following persons* (the
"Reporting Persons"):
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) Biotechnology Value Fund II, L.P. ("BVF2")
(iii) BVF Investments, L.L.C. ("Investments")
(iv) Investment 10, L.L.C. ("ILL10")
(v) BVF Partners L.P. ("Partners")
(vi) BVF Inc. ("BVF Inc.")
* Attached as Exhibit 1 is a copy of an agreement among the Reporting Persons
that this Schedule 13G and any amendments thereto shall be filed on behalf of
each of them.
Item 2(b). Address of Principal Business Office or, if none, Residence:
The principal business office of the Reporting Persons comprising the group
filing this Schedule 13G is located at 227 West Monroe Street, Suite 4800,
Chicago, Illinois, 60606.
Item 2(c). Citizenship or Place of Organization:
BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
ILL10: an Illinois limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 9 of 11 Pages
- -------------------------------- --------------------------
Item 2(d). Title of Class of Securities:
This Schedule 13G is being filed with respect to the common stock, par
value $0.0001 per share (the "Common Stock"), of Acadia Pharmaceuticals Inc. The
Reporting Persons' percentage ownership of Common Stock is based on 16,865,917
shares of Common Stock being outstanding.
As of August 20, 2004, (i) BVF beneficially owned 265,500 shares of Common
Stock; (ii) BVF2 beneficially owned 168,500 shares of Common Stock; (iii)
Investments beneficially owned 407,000 shares of Common Stock; and (iv) ILL10
beneficially owned 44,000 shares of Common Stock . Beneficial ownership by
Partners and BVF Inc. includes 885,000 shares of Common Stocks.
Item 2(e). CUSIP Number:
004225108
Item 3. If this Statement is Filed Pursuant to Rule 13d-1(B), or 13d-2(B) or (C)
Check Whether the Person Filing is: One of the Following
Not applicable as this Schedule 13G is filed pursuant to Rule 13d-1(c).
Item 4. Ownership
The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7)
on this Schedule 13G is hereby incorporated by reference.
Item 5. Ownership of 5 Percent or Less of a Class
If this statement is being filed to report the fact that as of the date
hereof the Reporting Persons have ceased to be the beneficial owner of more than
five percent of the class of securities check the following. | |
Item 6. Ownership of More than 5 Percent on Behalf of Another Person
Pursuant to the operating agreement of Investments, Partners is authorized,
among other things, to invest funds of Ziff Asset Management, L.P., the majority
member of Investments, in shares of Common Stock described herein and to vote
and exercise dispositive power over those securities. Partners and BVF Inc.
share voting and dispositive power over the shares of Common Stock beneficially
owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf
Partners acts as investment manager and, accordingly, Partners and BVF Inc. have
beneficial ownership of all of the shares of Common Stock held by such parties.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Securities Being Reported on By the Parent Holding Company
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 10 of 11 Pages
- -------------------------------- --------------------------
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: August 30, 2004
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BVF INVESTMENTS, L.L.C.
By: BVF Partners L.P., its manager
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
INVESTMENT 10, L.L.C.
By: BVF Partners L.P., its attorney-in-fact
By: BVF Inc., its general partner
- -------------------------------- --------------------------
CUSIP No. 004225108 13G Page 11 of 11 Pages
- -------------------------------- --------------------------
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
----------------------------
Mark N. Lampert
President
EXHIBIT 1
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, Investment 10, L.L.C., an Illinois limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.
Dated: August; 30, 2004
| BIOTECHNOLOGY VALUE FUND, L.P. | ||||||
By: |
BVF Partners L.P., its general partner | |||||
By: |
BVF Inc., its general partner | |||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||
BIOTECHNOLOGY VALUE FUND II, L.P. | ||||||
By: |
BVF Partners L.P., its general partner | |||||
By: |
BVF Inc., its general partner | |||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||
BVF INVESTMENTS, L.L.C. | ||||||
By: |
BVF Partners L.P., its manager | |||||
By: |
BVF Inc., its general partner | |||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||
INVESTMENT 10, L.L.C. | ||||||
By: |
BVF Partners L.P., its attorney-in-fact | |||||
By: |
BVF Inc., its general partner | |||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||
BVF PARTNERS L.P. | ||||||
By: |
BVF Inc., its general partner | |||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||
BVF INC. | ||||||
By: |
/s/ MARK N. LAMPERT Mark N. Lampert President | |||||